| [1] |
Wen XZ, Wang B, Jin QM, et al.
Thyroid antibody status is associated with central lymph node metastases in papillary thyroid carcinoma patients with Hashimoto's thyroiditis[J]. Ann Surg OncolAnn Surg Oncol, 2019, 26(6): 1751-1758.
doi: 10.1245/s10434-019-07256-4 |
| [2] |
Califano I, Deutsch S, Löwenstein A, et al.
Outcomes of patients with bone metastases from differentiated thyroid cancer[J]. Arch Endocrinol MetabArch Endocrinol Metab, 2018, 62(1): 14-20.
doi: 10.20945/2359-3997000000004 |
| [3] |
Pal P, Singh B, Kane S, et al.
Bone metastases in follicular carcinoma of thyroid[J]. Indian J Otolaryngol Head Neck SurgIndian J Otolaryngol Head Neck Surg, 2018, 70(1): 10-14.
doi: 10.1007/s12070-017-1170-x |
| [4] |
Orita Y, Sugitani I, Toda K, et al.
Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma[J]. ThyroidThyroid, 2011, 21(1): 31-35.
doi: 10.1089/thy.2010.0169 |
| [5] |
Higashino M, Ayani Y, Terada T, et al.
Clinical features of poorly differentiated thyroid papillary carcinoma[J]. Auris Nasus LarynxAuris Nasus Larynx, 2019, 46(3): 437-442.
doi: 10.1016/j.anl.2018.10.001 |
| [6] |
Lamartina L, Grani G, Durante C, et al. Recent advances in managing differentiated thyroid cancer[J/OL]. F1000Res, 2018, 7: 86[2020-09-26]. https://f1000research.com/articles/7-86/v1. DOI: 10.12688/f1000research.12811.1. |
| [7] |
Maruoka Y, Abe K, Baba S, et al.
Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma[J]. RadiologyRadiology, 2012, 265(3): 902-909.
doi: 10.1148/radiol.12112108 |
| [8] |
Lin YS, Li TJ, Liang J, et al.
Predictive value of preablation stimulated thyroglobulin and thyoglobulin/thyoid-stimulating hormone ratio in differetiated thyroid cancer[J]. Clin Nucl MedClin Nucl Med, 2011, 36(12): 1102-1105.
doi: 10.1097/RLU.0b013e3182291c65 |
| [9] |
Spencer CA.
Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 2004, 89(8): 3702-3704.
doi: 10.1210/jc.2004-0986 |
| [10] |
余永利, 罗全勇, 陈立波, 等.
分化型甲状腺癌术后131I治疗生存率分析[J]. 中华核医学杂志中华核医学杂志, 2006, 26(5): 261-263.
doi: 10.3760/cma.j.issn.2095-2848.2006.05.001 Yu YL, Luo QY, Chen LB, et al. Survival of patients with differentiated thyroid carcinoma after thyroidectomy and 131I therapy[J]. Chin J Nucl MedChin J Nucl Med, 2006, 26(5): 261-263. doi: 10.3760/cma.j.issn.2095-2848.2006.05.001 |
| [11] |
慕转转, 刘杰蕊, 鲁涛, 等.
血清Tg用于远处转移性分化型甲状腺癌131I治疗的疗效评估[J]. 中华核医学与分子影像杂志中华核医学与分子影像杂志, 2020, 40(6): 329-333.
doi: 10.3760/cma.j.cn321828-20200220-00055 Mu ZZ, Liu JR, Lu T, et al. Serum thyroglobulin in evaluating the response to 131I treatment in patients with distant metastatic differentiated thyroid cancer[J]. Chin J Nucl Med Mol ImagChin J Nucl Med Mol Imag, 2020, 40(6): 329-333. doi: 10.3760/cma.j.cn321828-20200220-00055 |
| [12] |
中华医学会核医学分会.
131I治疗分化型甲状腺癌指南(2014版)[J]. 中华核医学与分子影像杂志中华核医学与分子影像杂志, 2014, 34(4): 264-278.
doi: 10.3760/cma.j.issn.2095-2848.2014.04.002 Chinese Society of Nuclear Medicine. Clinical guidelines for 131I therapy of differentiated thyroid cancer (2014 version)[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2014, 34(4): 264-278. doi: 10.3760/cma.j.issn.2095-2848.2014.04.002 |